Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress

Stock Track

05/19

Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.

The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.

Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1144972324"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144972324\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144972324?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144972324","market":"sg","top_or_hot":-1,"title":"Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress","media":"Stock Track","content":"<p>Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.</p><p>The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.</p><p>Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-19 09:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.</p><p>The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.</p><p>Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBIO","symbol_name":"Zenas BioPharma Inc.","start_time":0,"source_url":"","article_id":"1144972324","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144972324","pubTimestamp":1779154765,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBIO":"Zenas BioPharma Inc."},"translate_title":"个股追踪|Zenas BioPharma因CEO购股及3期试验进展大涨9.17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBIO":1},"content_text":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}